Abstract
Chemotherapy for breast cancer is associated with the development of hot flashes, which can cause the patient considerable discomfort. Estrogen replacement therapy alleviates the number and severity of hot flashes but is contraindicated in such cases. Alternative methods to treat hot flashes are, therefore, urgently needed. Goodwin et al. have performed a 6-month, double-blind, randomized, placebo-controlled trial of megestrol acetate in 286 women with breast cancer. After 3 months, 65% of the patients receiving 20 mg megestrol acetate daily had achieved an appreciable reduction in the number of hot flashes (≥75% from baseline), compared with 48% in the 40 mg megestrol acetate group and 14% in the placebo group. The positive effects of megestrol acetate on hot flash frequency were maintained at 6 months. In this Practice Point commentary, I discuss the key findings of Goodwin et al. and place them into clinical context, highlighting the need for additional studies of hormonal therapies in women with breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Goodwin JW et al. (2008) Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group study 9626. J Clin Oncol 10: 1650–1656
Stanczyk FZ (1999) Structure-function relationships, potency, and pharmacokinetics of progestogens in treatment of the postmenopausal woman. In Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, edn 2, 105–124 (Ed Lobo RA) Philadelphia: Lippincott Williams and Wilkins
Gundersen S et al. (1990) Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 17: 45–50
Andersen J et al. (2008) Tamoxifen for one year versus two years versus 6 months of tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). Acta Oncol 47: 718–724
Abrams JS et al. (1990) Current status of high-dose progestins in breast cancer. Semin Oncol 17 (Suppl 9): 68–72
Bullock JL et al. (1975) Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 46: 165–168
Warren MP (2007) Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration. Mayo Clin Proc 82: 219–226
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has declared associations with the following companies: Barr Pharmaceuticals (consultant), Bradley Pharmaceuticals (Consultant), Eli Lilly (speakers bureau), Merck (speakers bureau), Novartis (speakers bureau and research support), Novo Nordisk (speakers bureau), Solvay Pharmaceuticals (research support), Warner Chilcott (consultant), and Wyeth (advisory board, speakers bureau and research support).
Rights and permissions
About this article
Cite this article
Warren, M. Is megestrol acetate a suitable option for treatment of hot flashes in women with breast cancer?. Nat Rev Endocrinol 4, 650–651 (2008). https://doi.org/10.1038/ncpendmet0977
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0977
